AI assistant
Telix Pharmaceuticals Ltd — Share Issue/Capital Change 2025
Dec 23, 2025
31324_rns_2025-12-23_d9b7e2ef-bf54-4e5c-845e-d83f3dea7f4b.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
==> picture [21 x 22] intentionally omitted <==
Announcement Summary
Entity name
TELIX PHARMACEUTICALS LIMITED
Date of this announcement
Wednesday December 24, 2025
The +securities the subject of this notification are:
+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX Total number of +securities to be issued/transferred
| Total number of | |||
|---|---|---|---|
| ASX +security | +securities to be | ||
| code | Security description | issued/transferred | Issue date |
| TLXAO | SHARE APPRECIATION RIGHTS | 742,992 | 24/10/2025 |
| TLXAW | PERFORMANCE SHARE APPRECIATION | 1,758,187 | 24/10/2025 |
| RIGHTS US 2025 |
Refer to next page for full details of the announcement
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
1 / 7
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
==> picture [21 x 22] intentionally omitted <==
Part 1 - Entity and announcement details
1.1 Name of entity
TELIX PHARMACEUTICALS LIMITED
We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.
1.2 Registered number type Registration number ACN 616620369
1.3 ASX issuer code
TLX
1.4 The announcement is
New announcement
1.5 Date of this announcement
24/12/2025
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
2 / 7
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
==> picture [21 x 22] intentionally omitted <==
Part 2 - Issue details
2.1 The +securities the subject of this notification are:
+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX
2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:
has an existing ASX security code ("existing class")
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
3 / 7
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
==> picture [21 x 22] intentionally omitted <==
Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B
ASX +security code and description
TLXAO : SHARE APPRECIATION RIGHTS
Date the +securities the subject of this notification were issued
24/10/2025
Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Yes Were any of the +securities issued to +key management personnel (KMP) or an +associate? No Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms
Refer to Telix's Remuneration report, within its 2024 Annual Report and to Telix's 2025 Annual General Meeting Notice of Meeting for Performance Share Appreciation Rights valuation methodology, accessible at https://ir.telixpharma.c om/reports Any other information the entity wishes to provide about the +securities the subject of this notification Performance Share Appreciation Rights granted to Telix employees ex-US as 2025 Long Term Incentive. Vesting is subject to achievement of performance conditions and the terms of Telix's Equity Incentive Plan rules, with a measurement period of 2025-2027, and a two year exercise period following vesting.
Issue details
Number of +securities 742,992
ASX +security code and description
TLXAW : PERFORMANCE SHARE APPRECIATION RIGHTS US 2025
Date the +securities the subject of this notification were issued
24/10/2025
Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Yes
Were any of the +securities issued to +key management personnel (KMP) or an +associate? No
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
4 / 7
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
==> picture [21 x 22] intentionally omitted <==
Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms
Refer to Telix's Remuneration report, within its 2024 Annual Report and to Telix's 2025 Annual General Meeting Notice of Meeting for Performance Share Appreciation Rights valuation methodology, accessible at https://ir.telixpharma.c om/reports
Any other information the entity wishes to provide about the +securities the subject of this notification
Performance Share Appreciation Rights granted to Telix US employees as 2025 Long Term Incentive. Vesting is subject to achievement of performance conditions and the terms of Telix's Equity Incentive Plan rules, with a measurement period of 2025-2027, and a two year exercise period following vesting. Rights over Telix ordinary shares to be delivered as American Depositary Shares to US domiciled employees.
Issue details
Number of +securities
1,758,187
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
5 / 7
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
==> picture [21 x 22] intentionally omitted <==
Part 4 - +Securities on issue
Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:
The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.
4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)
| Total number of | |
|---|---|
| ASX +security code and description | +securities on issue |
| TLX : ORDINARY FULLY PAID | 338,721,355 |
| 4.2 Unquoted +securities (Total number of each +class of +securities issued but | not quoted on ASX) |
| Total number of | |
| ASX +security code and description | +securities on issue |
| TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL | 80,000 |
| TLXAR : PERFORMANCE RIGHTS | 9,965,235 |
| TLXAP : SHARE RIGHTS | 1,265,004 |
| TLXAO : SHARE APPRECIATION RIGHTS | 15,623,553 |
| TLXAT : CONVERTIBLE NOTES | 3,250 |
| TLXAM : OPTION EXPIRING 20-JUL-2026 EX $5.37 | 208,397 |
| TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL | 100,000 |
| TLXAU : DEFERRED SHARE RIGHTS EX-US 2024 | 10,561 |
| TLXAV : DEFERRED SHARE RIGHTS US 2024 | 10,342 |
| TLXAW : PERFORMANCE SHARE APPRECIATION RIGHTS US 2025 | 4,437,433 |
| TLXAL : OPTION EXPIRING 27-JAN-2026 EX $4.38 | 81,411 |
| TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS | 440,000 |
4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
6 / 7
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
==> picture [21 x 22] intentionally omitted <==
Part 5 - Other Listing Rule requirements
5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1? Yes
5.1a Select the number of the applicable exception in Listing Rule 7.2
13
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities
7 / 7